New standards for first-line treatment of liver cancer! Wessa and Merca East launched Lenvima (Le Weima) in Japan, China in early September has:

Eisai, a Japanese drug company, and MSD K.K., a Japanese subsidiary of Merca East, recently jointly announced that two companies have begun joint marketing of the anti-cancer drug Lenvima (Chinese brand name: Le Weimar, generic name: methadone, lenvatinib mesylate). In March this year, Wessa and Mercadon reached a global co-development and common commercialization strategic partnership with Lenvima through a subsidiary.
Lenvima is an oral polyceptamate tyrosine kinase (RTK) inhibitor developed in-house by Aodes, with novel binding patterns that inhibit other angiogenesic and carcinogenic signaling path pathogens associated with tumor proliferation(including platea-derived growth factor (PDGF) of the binders PDGFR, KIT and RE In addition to T), it is also ability to selectively inhibit kinase activity of vascular endostropheric growth factor (VEGF1, VEGFR2, VEGFR3) and fibrous growth factor (FGF) subjects (FGFR1, FGFR2, FGFR3, FGFR3).
To date, Lenvima has been approved by more than 50 countries and regions, including the United States, Japan, Europe and Asia, for resuscable thyroid cancer, and has been approved by more than 40 countries and regions, including the United States and the European Union, for second-line treatment of renal cell carcinoma (RCC). In addition, Lenvima has been approved for treatment of hepatocellular carcinoma (HCC) in Japan, the United States, Europe, China and other countries and regions. In Japan, about 4,500 patients have been treated with Lenvima since HCC adaptation was approved in March 2018.Lenvima: China approved the first new drug for hepatocellular carcinoma in 10 years
In the Chinese market, Lenvima was approved in early September 2018 as a single-drug therapy for patients with non-excisible hepatocellular carcinoma (HCC) who have not been treated systematically in the past. China, the world's largest patient of liver cancer, marks Lenvima's first entry into the country and the first new treatment approved in China in a decade as a first-line treatment for hepatocellular carcinoma (HCC).
, liver cancer is the second leading cause of cancer deaths, with 780,000 new cases each year (71,000 new in Europe) and about 750,000 deaths each year. Hepatocellular carcinoma (HCC) accounts for 90% of primary liver cancer cases, the early stage of HCC can be treated by a variety of means, including surgical excision, radio frequency ablation, waterless ethanol injection, chemotherapy embolism treatment and so on, but the treatment options of non-excisive HCC are very limited, the prognosis is very poor, resulting in a significant unsolved medical needs in this field. Previously, Bayer's targeted cancer drug, Nexavar, was the only molecularly targeted drug approved for first-line treatment of non-removable HCC.
there are large regional differences in liver cancer, with the majority of cases occurring in Asia, first in China and then in Africa. Hepatocellular carcinoma accounts for about 85%-90% of primary liver cancer. Hepatocellular carcinoma is associated with chronic liver disease, especially cirrhosis. The main causes of cirrhosis include hepatitis B virus and hepatitis C virus infection. However, according to a recent survey, non-hepatitis B/C-hepatocellular carcinoma is on the rise. (Bio Valley)